AU602129B2 - Creation of Inventions and Patents with Artificial Intelligence

AU602129B2 – Method for the determination of a differential white blood cell count
– Google Patents

AU602129B2 – Method for the determination of a differential white blood cell count
– Google Patents
Method for the determination of a differential white blood cell count

Download PDF
Info

Publication number
AU602129B2

AU602129B2
AU62016/86A
AU6201686A
AU602129B2
AU 602129 B2
AU602129 B2
AU 602129B2
AU 62016/86 A
AU62016/86 A
AU 62016/86A
AU 6201686 A
AU6201686 A
AU 6201686A
AU 602129 B2
AU602129 B2
AU 602129B2
Authority
AU
Australia
Prior art keywords
composition
white blood
sample
reagent solution
cell count
Prior art date
1985-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU62016/86A
Other versions

AU6201686A
(en

Inventor
John F. Cremins
Young Ran Kim
Michael J. Malin
Louis D. Sclafani Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Corp

Original Assignee
Technicon Instruments Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1985-09-06
Filing date
1986-08-27
Publication date
1990-10-04

1986-08-27
Application filed by Technicon Instruments Corp
filed
Critical
Technicon Instruments Corp

1987-03-12
Publication of AU6201686A
publication
Critical
patent/AU6201686A/en

1990-10-04
Application granted
granted
Critical

1990-10-04
Publication of AU602129B2
publication
Critical
patent/AU602129B2/en

2006-08-27
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

238000000034
method
Methods

0.000
title
claims
description
32

210000000265
leukocyte
Anatomy

0.000
title
claims
description
29

238000004820
blood count
Methods

0.000
title
claims
description
12

239000000243
solution
Substances

0.000
claims
description
58

WSFSSNUMVMOOMR-UHFFFAOYSA-N
Formaldehyde
Chemical compound

O=C
WSFSSNUMVMOOMR-UHFFFAOYSA-N
0.000
claims
description
54

239000000203
mixture
Substances

0.000
claims
description
39

239000003153
chemical reaction reagent
Substances

0.000
claims
description
30

150000005846
sugar alcohols
Chemical class

0.000
claims
description
19

WQZGKKKJIJFFOK-GASJEMHNSA-N
Glucose
Natural products

OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-GASJEMHNSA-N
0.000
claims
description
18

235000000346
sugar
Nutrition

0.000
claims
description
18

239000008121
dextrose
Substances

0.000
claims
description
15

239000011541
reaction mixture
Substances

0.000
claims
description
14

239000004094
surface-active agent
Substances

0.000
claims
description
11

FBPFZTCFMRRESA-FSIIMWSLSA-N
D-Glucitol
Natural products

OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO
FBPFZTCFMRRESA-FSIIMWSLSA-N
0.000
claims
description
9

239000000872
buffer
Substances

0.000
claims
description
9

239000011734
sodium
Substances

0.000
claims
description
9

239000000600
sorbitol
Substances

0.000
claims
description
9

150000003839
salts
Chemical class

0.000
claims
description
8

DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical group

[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
claims
description
7

238000010186
staining
Methods

0.000
claims
description
7

FBPFZTCFMRRESA-JGWLITMVSA-N
D-glucitol
Chemical compound

OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
FBPFZTCFMRRESA-JGWLITMVSA-N
0.000
claims
description
6

WQZGKKKJIJFFOK-VFUOTHLCSA-N
beta-D-glucose
Chemical compound

OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-VFUOTHLCSA-N
0.000
claims
description
6

229930040373
Paraformaldehyde
Natural products

0.000
claims
description
5

108091006629
SLC13A2
Proteins

0.000
claims
description
5

-1
alkali metal salt
Chemical class

0.000
claims
description
5

210000000601
blood cell
Anatomy

0.000
claims
description
5

238000002156
mixing
Methods

0.000
claims
description
5

229920002866
paraformaldehyde
Polymers

0.000
claims
description
5

229910052783
alkali metal
Inorganic materials

0.000
claims
description
4

238000010438
heat treatment
Methods

0.000
claims
description
4

FBPFZTCFMRRESA-KVTDHHQDSA-N
D-Mannitol
Chemical compound

OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
FBPFZTCFMRRESA-KVTDHHQDSA-N
0.000
claims
description
3

229930195725
Mannitol
Natural products

0.000
claims
description
3

229910001514
alkali metal chloride
Inorganic materials

0.000
claims
description
3

239000007864
aqueous solution
Substances

0.000
claims
description
3

150000003841
chloride salts
Chemical class

0.000
claims
description
3

239000000594
mannitol
Substances

0.000
claims
description
3

235000010355
mannitol
Nutrition

0.000
claims
description
3

229930091371
Fructose
Natural products

0.000
claims
description
2

239000005715
Fructose
Substances

0.000
claims
description
2

RFSUNEUAIZKAJO-ARQDHWQXSA-N
Fructose
Chemical compound

OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O
RFSUNEUAIZKAJO-ARQDHWQXSA-N
0.000
claims
description
2

229930006000
Sucrose
Natural products

0.000
claims
description
2

CZMRCDWAGMRECN-UGDNZRGBSA-N
Sucrose
Chemical compound

O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
CZMRCDWAGMRECN-UGDNZRGBSA-N
0.000
claims
description
2

150000008051
alkyl sulfates
Chemical class

0.000
claims
description
2

125000004432
carbon atom
Chemical group

0.000
claims
description
2

239000005720
sucrose
Substances

0.000
claims
description
2

101100283604
Caenorhabditis elegans pigk-1 gene
Proteins

0.000
claims
1

FHNINJWBTRXEBC-UHFFFAOYSA-N
Sudan III
Chemical compound

OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1
FHNINJWBTRXEBC-UHFFFAOYSA-N
0.000
claims
1

229910052739
hydrogen
Inorganic materials

0.000
claims
1

239000001257
hydrogen
Substances

0.000
claims
1

125000004435
hydrogen atom
Chemical class

[H]*

0.000
claims
1

150000002978
peroxides
Chemical class

0.000
claims
1

210000003743
erythrocyte
Anatomy

0.000
description
22

210000004698
lymphocyte
Anatomy

0.000
description
12

210000004369
blood
Anatomy

0.000
description
11

239000008280
blood
Substances

0.000
description
11

210000004027
cell
Anatomy

0.000
description
11

210000000440
neutrophil
Anatomy

0.000
description
8

MHAJPDPJQMAIIY-UHFFFAOYSA-N
Hydrogen peroxide
Chemical compound

OO
MHAJPDPJQMAIIY-UHFFFAOYSA-N
0.000
description
7

102000003992
Peroxidases
Human genes

0.000
description
7

108040007629
peroxidase activity proteins
Proteins

0.000
description
7

KCXVZYZYPLLWCC-UHFFFAOYSA-N
EDTA
Chemical compound

OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O
KCXVZYZYPLLWCC-UHFFFAOYSA-N
0.000
description
6

HEMHJVSKTPXQMS-UHFFFAOYSA-M
Sodium hydroxide
Chemical compound

[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
6

229960001484
edetic acid
Drugs

0.000
description
6

210000003979
eosinophil
Anatomy

0.000
description
6

239000008363
phosphate buffer
Substances

0.000
description
6

XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Chemical compound

O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
6

230000009089
cytolysis
Effects

0.000
description
5

QXNVGIXVLWOKEQ-UHFFFAOYSA-N
Disodium
Chemical class

[Na][Na]
QXNVGIXVLWOKEQ-UHFFFAOYSA-N
0.000
description
4

FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound

[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
4

238000009472
formulation
Methods

0.000
description
4

230000002452
interceptive effect
Effects

0.000
description
4

210000001616
monocyte
Anatomy

0.000
description
4

239000002244
precipitate
Substances

0.000
description
4

238000000926
separation method
Methods

0.000
description
4

238000006243
chemical reaction
Methods

0.000
description
3

238000001514
detection method
Methods

0.000
description
3

230000000694
effects
Effects

0.000
description
3

239000008103
glucose
Substances

0.000
description
3

230000007935
neutral effect
Effects

0.000
description
3

JKMHFZQWWAIEOD-UHFFFAOYSA-N
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
Chemical compound

OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1
JKMHFZQWWAIEOD-UHFFFAOYSA-N
0.000
description
2

DVLFYONBTKHTER-UHFFFAOYSA-N
3-(N-morpholino)propanesulfonic acid
Chemical compound

OS(=O)(=O)CCCN1CCOCC1
DVLFYONBTKHTER-UHFFFAOYSA-N
0.000
description
2

LVSPDZAGCBEQAV-UHFFFAOYSA-N
4-chloronaphthalen-1-ol
Chemical compound

C1=CC=C2C(O)=CC=C(Cl)C2=C1
LVSPDZAGCBEQAV-UHFFFAOYSA-N
0.000
description
2

RGHNJXZEOKUKBD-UHFFFAOYSA-N
D-gluconic acid
Natural products

OCC(O)C(O)C(O)C(O)C(O)=O
RGHNJXZEOKUKBD-UHFFFAOYSA-N
0.000
description
2

RGHNJXZEOKUKBD-SQOUGZDYSA-N
Gluconic acid
Natural products

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O
RGHNJXZEOKUKBD-SQOUGZDYSA-N
0.000
description
2

DGAQECJNVWCQMB-PUAWFVPOSA-M
Ilexoside XXIX
Chemical compound

C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+]
DGAQECJNVWCQMB-PUAWFVPOSA-M
0.000
description
2

238000004458
analytical method
Methods

0.000
description
2

238000004925
denaturation
Methods

0.000
description
2

230000036425
denaturation
Effects

0.000
description
2

239000000834
fixative
Substances

0.000
description
2

239000000174
gluconic acid
Substances

0.000
description
2

235000012208
gluconic acid
Nutrition

0.000
description
2

238000002347
injection
Methods

0.000
description
2

239000007924
injection
Substances

0.000
description
2

KWGKDLIKAYFUFQ-UHFFFAOYSA-M
lithium chloride
Chemical compound

[Li+].[Cl-]
KWGKDLIKAYFUFQ-UHFFFAOYSA-M
0.000
description
2

BDAGIHXWWSANSR-UHFFFAOYSA-N
methanoic acid
Natural products

OC=O
BDAGIHXWWSANSR-UHFFFAOYSA-N
0.000
description
2

235000019799
monosodium phosphate
Nutrition

0.000
description
2

LWIHDJKSTIGBAC-UHFFFAOYSA-K
potassium phosphate
Substances

[K+].[K+].[K+].[O-]P([O-])([O-])=O
LWIHDJKSTIGBAC-UHFFFAOYSA-K
0.000
description
2

230000006920
protein precipitation
Effects

0.000
description
2

229910052708
sodium
Inorganic materials

0.000
description
2

239000011780
sodium chloride
Substances

0.000
description
2

AJPJDKMHJJGVTQ-UHFFFAOYSA-M
sodium dihydrogen phosphate
Chemical compound

[Na+].OP(O)([O-])=O
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
0.000
description
2

229910000162
sodium phosphate
Inorganic materials

0.000
description
2

CMCBDXRRFKYBDG-UHFFFAOYSA-N
1-dodecoxydodecane
Chemical compound

CCCCCCCCCCCCOCCCCCCCCCCCC
CMCBDXRRFKYBDG-UHFFFAOYSA-N
0.000
description
1

LTMRRSWNXVJMBA-UHFFFAOYSA-L
2,2-diethylpropanedioate
Chemical compound

CCC(CC)(C([O-])=O)C([O-])=O
LTMRRSWNXVJMBA-UHFFFAOYSA-L
0.000
description
1

OSWFIVFLDKOXQC-UHFFFAOYSA-N
4-(3-methoxyphenyl)aniline
Chemical compound

COC1=CC=CC(C=2C=CC(N)=CC=2)=C1
OSWFIVFLDKOXQC-UHFFFAOYSA-N
0.000
description
1

239000007991
ACES buffer
Substances

0.000
description
1

CPELXLSAUQHCOX-UHFFFAOYSA-M
Bromide
Chemical compound

[Br-]
CPELXLSAUQHCOX-UHFFFAOYSA-M
0.000
description
1

KRHYYFGTRYWZRS-UHFFFAOYSA-M
Fluoride anion
Chemical compound

[F-]
KRHYYFGTRYWZRS-UHFFFAOYSA-M
0.000
description
1

239000007995
HEPES buffer
Substances

0.000
description
1

WHXSMMKQMYFTQS-UHFFFAOYSA-N
Lithium
Chemical compound

[Li]
WHXSMMKQMYFTQS-UHFFFAOYSA-N
0.000
description
1

239000007993
MOPS buffer
Substances

0.000
description
1

229920003171
Poly (ethylene oxide)
Polymers

0.000
description
1

229930182556
Polyacetal
Natural products

0.000
description
1

229920001213
Polysorbate 20
Polymers

0.000
description
1

ZLMJMSJWJFRBEC-UHFFFAOYSA-N
Potassium
Chemical compound

[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
description
1

230000002159
abnormal effect
Effects

0.000
description
1

238000010521
absorption reaction
Methods

0.000
description
1

239000000654
additive
Substances

0.000
description
1

210000003651
basophil
Anatomy

0.000
description
1

230000015572
biosynthetic process
Effects

0.000
description
1

239000006285
cell suspension
Substances

0.000
description
1

239000002738
chelating agent
Substances

0.000
description
1

230000000093
cytochemical effect
Effects

0.000
description
1

239000008367
deionised water
Substances

0.000
description
1

229910021641
deionized water
Inorganic materials

0.000
description
1

238000002405
diagnostic procedure
Methods

0.000
description
1

MTHSVFCYNBDYFN-UHFFFAOYSA-N
diethylene glycol
Chemical compound

OCCOCCO
MTHSVFCYNBDYFN-UHFFFAOYSA-N
0.000
description
1

229940079593
drug
Drugs

0.000
description
1

239000003814
drug
Substances

0.000
description
1

210000003617
erythrocyte membrane
Anatomy

0.000
description
1

235000019253
formic acid
Nutrition

0.000
description
1

229930182830
galactose
Natural products

0.000
description
1

229910052736
halogen
Inorganic materials

0.000
description
1

150000002367
halogens
Chemical class

0.000
description
1

XMBWDFGMSWQBCA-UHFFFAOYSA-N
hydrogen iodide
Chemical compound

I
XMBWDFGMSWQBCA-UHFFFAOYSA-N
0.000
description
1

239000000819
hypertonic solution
Substances

0.000
description
1

229940021223
hypertonic solution
Drugs

0.000
description
1

238000011534
incubation
Methods

0.000
description
1

239000004615
ingredient
Substances

0.000
description
1

230000005764
inhibitory process
Effects

0.000
description
1

229910052744
lithium
Inorganic materials

0.000
description
1

230000000873
masking effect
Effects

0.000
description
1

238000005259
measurement
Methods

0.000
description
1

229910052751
metal
Inorganic materials

0.000
description
1

239000002184
metal
Substances

0.000
description
1

230000003287
optical effect
Effects

0.000
description
1

230000003647
oxidation
Effects

0.000
description
1

238000007254
oxidation reaction
Methods

0.000
description
1

239000000244
polyoxyethylene sorbitan monooleate
Substances

0.000
description
1

235000010482
polyoxyethylene sorbitan monooleate
Nutrition

0.000
description
1

229920006324
polyoxymethylene
Polymers

0.000
description
1

229920000053
polysorbate 80
Polymers

0.000
description
1

229910052700
potassium
Inorganic materials

0.000
description
1

239000011591
potassium
Substances

0.000
description
1

235000011009
potassium phosphates
Nutrition

0.000
description
1

238000001556
precipitation
Methods

0.000
description
1

238000009877
rendering
Methods

0.000
description
1

239000001488
sodium phosphate
Substances

0.000
description
1

235000011008
sodium phosphates
Nutrition

0.000
description
1

150000008163
sugars
Chemical class

0.000
description
1

239000000725
suspension
Substances

0.000
description
1

Classifications

G—PHYSICS

G01—MEASURING; TESTING

G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00

G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

G—PHYSICS

G01—MEASURING; TESTING

G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

G01N1/00—Sampling; Preparing specimens for investigation

G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q

G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

G01N2001/305—Fixative compositions

Description

I11111 IjIH.
2 5 111,11L.
J1J.8 O68L9S9″EZ zAXMAnsj bdouwpj!!q631p)q a ZAXMAn-‘sNOdONNhIHsj3GqV 1d 0 11111 1111.25 ~j14 D
I~.
II
[I
9) A 0212 9 COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE Class Application Number: 2 Lodged: Form Int. Class Complete Specification-Lodrad: Accpted: PiA~lished: ‘riority: Related Art: Name of Applicant: Address of Applicant: Actual Inventor: dcumntcontainsth amendcments Ylacde under ~Section 49 and is correct for ~Printing.
TO BE COMPLETED BY APPLICANT TECH-NICON INSTRUIYIENTS CORPORATION 511 Benedict Avenue, Tarrytown, New York,
U.S.A.
John F. CREMINS, Michael J. MALIN, Young Ran KIM, Louis D. SCLAFANI IV.
Address for Service: SANDERCOCK, SM’ITH BEADLE 207 Riversdale Road, Box 410) Hawthorn, Victoria, 3122 Complete Specification for the invention entitled: METHOD FOR THE DETERMINATION OF A DIFFERENTIAL WHITE BLOOD CELL COUNT.
The following statement is a full description of this invention, including the best method of performing it known to me:- Signature of
TO
ipplicant or Australian attorney (Signature) SANDERCOCK, SMITH BEADLE THE COMMISSIONER OF PATENTS SANERCCK, SMITH BEADLE This form must be accompanied by either a provisional specification (Form 9 and true copy) or by a complete specification (Form 10 and true copy).
6380 There are five classes of normal white blood cells or leukocytes: neutrophils, lymphocytes, monocytes, eosinophils and basophils. It is a known medical diagnostic procedure to examine a dried, stained smear of blood on a microscope slide to determine the relative proportions of these five normal types of white blood cells, as well as the concentration of any abnormal cells. Such procedure is referred to as a differential white blood cell count and is described in Miale, “Laboratory Medicine Hematology”, pp. 822-830, 1126, 1127 and 1130, C.V. Mosby Company, St.
Louis, Missouri (1967).
15 Recently, automated processes and automated flow system apparatus therefor have been developed to ease the burden of differential white blood cell counting, such as described in U.S. Patents 3,741,875 and 4,099,917. These use cytochemical procedures to specifically identify and label individual cell types.
The procedure for preparing a cell suspension for use in such systems comprises treating an uncoagulated blood sample with a surfactant for about 1.5 minutes to Sprecondition the red blood cells for lysis; thereafter adding a fixative to the cells for about 1 minute while maintaining a neutral pH; and incubating the mixture at 58 0 C to 60 0 C for about 2 minutes to lyse the red blood cells and fix the white blood cells, as described in U.S. Patent 4,099,917. It is imperative in such processes that all of the red blood cells 3 be lysed because the red blood cells outnumber the white Senior Vice President, General Title Counsel Assistant Secretary To: The Commissioner of Patents, Australia 2 1 blood cells by about 700 to 1. Because of this, even if one 2 percent of the red blood cells remain unlysed, the 3 differential white blood cell count cannot be accurately 4 arrived at.
A major drawback to the prior art methods is the 6 relatively extended period of time each analysis requires, 7 as much as five minutes just to prepare the cell 8 suspension, thereby rendering such methods undesirable for 9 emergency sample analysis or for other situations in which rapid results are desirable. Accordingly, there is need for 11 a method for the determination of a differential white 12 bloood cell count which is relatively rapid as compared to 13 the prior art procedures. Such a method would have to 14 completely lyse the red blood cells in the sample without damaging the white blood cells, causing no extra-cellular 16 precipitation or clumping of cells, since such precipitates 17 or cell clumps could generate ambiguities in the cell 18 detecting and recognizing phase of the process.
19 The present invention relates to a differential white 20 blood cell count determining composition comprising, in 21 admixture, an aqueous solution of: 22 a) a surfactant; 23 b) formaldehyde or paraformaldehyde; 24 c) a non reducing sugar or sugar alcohol; and d) a buffer 26 The present invention also relates to a method for the 27 rapid determination of a differential white blood cell count 28 in a sample. More particularly, the invention relates to a 0b I 229 method which comprises: 900220,!mwspeOll,tech.cla, PATEN 0F’ A -3- 1 a) preparing or utilizing a reagent solution comprising formaldehyde or paraformaldehyde; a surfactant; a sugar or sugar alcohol; and a buffer; and b) rapidly mixing said reagent solution with the sample to be analyzed to form a reaction mixture, wherein both said reagent solution and said sample are initially at a temperature of from about 20 0 C to about 28 0 C; and c) heating said reaction mixture to a temperature of from about 62 0 C to about 72 0 C within about 30 seconds in order to lyse the red blood cells in said sample and fix the white blood cells in said sample.
The present invention relates to a method for the to*« rapid determination of a differential white blood cell count and solution used therefor.
Formaldehyde or paraformaldehyde is used in the S% reagent solution of this invention as a fixative for the t white blood cells. Preferably, formaldehyde is used and is 2 present in said solution in an amount of from about 4.5% to about Ideally, formaldehyde is present in an amount of from about 5.3% to about 5.9%.
The surfactant present in the reagent solution of this invention is any one which will lyse the red blood cells (RBCs). For instance, the surfactant may be a neutral surfactant such as polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 23 monolauryl ether or polyoxyethylene sorbitan monooleate, each of which may be readily synthesized by the skilled artisan, but is preferably the class of alkali metal salts of an alkyl sulfate having from about 10 to about 16 carbon atoms. The preferred alkali metal cations are sodium, potassium and lithium. The more preferred -4- Ssurfactants are the alkali metal dodecyl sulfates with sodium dodecyl sulfate being most preferred. The surfactant should be present in the reagent solution of this invention in an amount of from about 3.1 millimolar (mM) to about 4.5 mM.
For sodium dodecyl sulfate, this molar concentration corresponds to about 0.9 g/L to about 1.3 g/L.
The sugar or sugar alcohol is present in the reagent solution of this invention in order to raise the signal-to-noise ratio of the lymphocytes to increase their ability to be “read” by electro optical detectors).
Suitable sugars or sugar alcohols include sucrose, fructose, dextrose, sorbitol and mannitol. The choice between a sugar or a sugar alcohol should and can routinely be made by the skilled artisan based upon the particular requisites of the 0 situation. Surprisingly, though, it has been found that when 5 a sugar alcohol is used the reagent solution is more stable over time under stress conditions than when a reducing sugar Ssuch as glucose is used.
The reason for the increased stability of the Sreagent solution when a sugar alcohol is used rather than a I tt reducing sugar appears to be that a reducing sugar such as ti
I
glucose may, over time, be air oxidized to form gluconic acid, see, Nishikido, Jr., Tamura, W. and Fuknoka, Y., Jap. Kokai Tokyo Koho 80 40, 606, Chem. Abs. 93:22120d (1950). If gluconic acid is present the pH of the solution is lowered. Once the pH falls outside of the range of this invention, the method of this invention becomes less accurate due to non-lysis of red cells. A sugar alcohol cannot be air-oxidized. In addition, a sugar alcohol may chemically Scombine with formaldehyde to form a polyacetal, thereby preventing the oxidation of formaldehyde to formic acid which, if formed, would lower the pH of the formulation.
1 The preferred sugar to be used in the reagent solution of this invention is dextrose (which is not a reducing sugar) and the preferred sugar alcohol is sorbitol, although as indicated, sugar alcohol is preferred. Dextrose or sorbitol should be present in an amount of from about to about 13.5% weight/volume Ideally, dextrose or sorbitol are present in the reagent solution of this invention in an amount of from about 11.0% to about 12.0% When a sugar other than dextrose or a sugar alcohol other than sorbitol is used, the amount should be adjusted so that the alternate sugar or sugar alcohol is present on approximately an equimolar basis with dextrose or sorbitol.
If desired, a salt may also be included in the reagent solution. Salts suitable for use in the present r, invention may be alkali metal chloride salts such as NaC1, KC1 and LiCl. Ideally, the salt is NaC1. Such salt is may optionally be present because it may aid in discriminating the neutrophils from the eosinophils by causing a difference in peroxidase stain intensity using light scatter/absorption Soptics. Other halogen salts fluoride, bromide and iodide) over-inhibit peroxidase activity of the neutrophils, t t thereby preventing the discrimination of neutrophils from the other unstained white blood cells (WBCs). The salt, when used, should preferably be present in an amount of from about 2 68 mM to about 103 mM. When NaC1 is used as the salt, it is present in said reagent solution in an amount of from about 0.4% to about 0.6% The buffer or mixture of buffers useful in this invention should be those suitable for maintaining the pH of the reagent solution at from about 6.6 to about 7.6, preferably from about 6.9 to about 7.3. Suitable buffers -6- 1 include sodium or potassium phosphates, diethyl malonate, 3-(N-morpholino) propane sulfonic acid, (MOPS), N-2-acetamido-2-aminoethane sulfonic acid (ACES), and 4-(2-hydroxyethyl)-l-piperazine-ethansulfonic acid (HEPES).
Preferred is a mixture of Na2HPO 4 and NaH2PO 4 As indicated, the buffers should be present in the reagent solution of this invention in an amount suitable to maintain the pH of the solution at approximately neutral levels. For instance, when a mixture of Na 2
HPO
4 and NaH 2
PO
4 is used, the mixture should contain a mole ratio of Na 2 HPO to NaH PO which is from 2 4 2 4 about 2.04:1 to about 0.81:1 to produce a series of solutions with a pH range of about 6.9 to about 7.3. The concentration of such mixture in the reagent solution of this invention is from about 0.075 Molar to about 0.125 M.
The reagent solution useful in the practice of this :15 invention is an aqueous solution and, preferably, deionized water used. The solution is prepared by combining the S” ingredients, in admixture, in water. A close watch should be t Vt maintained on the pH of the solution to ensure that it stays 2 within the desired range. Additionally, the skilled artisan may also include other additives in the reagent solution as desired. For instance, ethylenediamine tetracetic acid L’ (EDTA) may be included as a metal chelator.
In practicing the method of this invention, the reagent solution is rapidly mixed with the sample to be analyzed to form the reaction mixture. Uniform mixture should occur within 5 seconds of the time the reagent solution and the blood sample come into contact with each other. If the two are not uniformly mixed rapidly, fixation of RBCs will occur which prevents complete lysis of the RBCs, thereby greatly impairing the accuracy of the differential WBC count obtained from the practice of this invention.
-7- When mixed, the reagent solution and the blood sample should initially be at room temperature (about 20 0 C to 28 0 C) in order to ensure that the critical heating profile is maintained. The reaction mixture is then rapidly heated to a temperature of from about 62 0 C to about 72 0 C, ideally from about 64 0 C to about 68 0 C, preferably by injection into an automated hematology analyzer maintained at a suitably elevated temperature. Kinetic measurements indicate that the reaction mixture temperature is brought to from about 35°C to about 42 0 C substantially immediately upon injection. The subsequent temperature rise begins from that point. The heating of the reaction mixture should take place within about 30 seconds, preferably within about 20 seconds, S otherwise RBC fixation will occur, preventing lysis, and thereby interfering with the accuracy of the differential WBC 5 count.
Immediately thereafter, a staining mixture ,I *comprising hydrogen peroxide and a suitable chromogen such as r4-chloro-l-naphthol is mixed with the reaction mixture. The initial temperature of the staining mixture may be room temperature and, ideally but not necessarily, the temperature L; t after mixing the staining mixture with the reaction mixture is increased to from about 62°C to about 72 0 C, preferably from about 63 0 C to about 69 0 C in a period of within about seconds preferably from about 8 to about 15 seconds, in order 2 5 to stain the neutrophils and eosinophils which are peroxidase active.
In practice, the reaction may proceed as follows: an automated hematology analyzer reaction chamber is maintained at a temperature of approximately 72 0 C. 12.0 ul I 30 of whole blood and 250 ul of the reagent solution disclosed 11—_11111~-1_1~ -8herein are simultaneously injected into the system at room temperature, thereby rapidly mixing the two to form the reaction mixture, which is then incubated for up to about seconds, during which time the temperature of the mixture is increased to from about 62 0 C to about 72 0 C. At the end of the incubation period, the RBCs are completely lysed and the WBCs fixed.
Immediately thereafter 125 ul of a chromogen mixture (for example, 0.8% 4-chloro-l-naphthol in oxygiethanol) is simultaneously injected with 250 ul of a hydrogen peroxide solution comprising 0.3% hydrogen peroxide.
Both reagents are initially at room temperature, but due to the temperature of the reaction chamber, the staining mixture temperature is increased to from about 63 0 C to about 69 0
C
within about 30 seconds, at which time the peroxidase staining of neutrophils and eosinophils is completed.
S|Fig. 1 illustrates a cytogram which is obtained from the electro-optical detection apparatus of an automated S hematology analyzer. This figure shows the four WBC types Sdifferentiated by the method of this invention: 1, lymphocytes; 2, monocytes; 3, neutrophils, and 4, eosinophils. The cytogram also shows noise, 5, arising from I platelets and red cell ghosts.
Another significant aspect of this invention is the S 2 high solute concentration of the reagent solution. The relatively high formaldehyde or paraformaldehyde and sugar or sugar alcohol contents combine to yield a total molarity of the reagent solution in excess of about 2.0 M/L. The effect Sof this hypertonic solution on blood cells causes them to Screnate (shrink due to osmotically-driven dehydiation). It is known that crenation of the lympocytes enhances their detection over noise thereby improving the accuracy of the differential WBC count determination.
-9- Although the procedure of the subject invention is illustrated using automated equipment, it will be readily observed by those skilled in the art that it may also be applicable to manual methods. Further, the procedure of this invention has been illustrated using whole blood to arrive at the differential WBC count therein. It will be appreciated by those skilled in the art that the invention may also be employed with stock calibrator, control and other solutions of blood cells which are specifically prepared to calibrate and maintain apparatus accuracy. The use of the term “sample” herein is specifically intended to include either S ,tt whole blood or other solutions which contain blood cells.
The following examples are illustrative of the invention.
fr ti 4 Whereas they are presented to further facilitate an f, t understanding of the inventive concepts, they are in no way S 15 to be interpreted as limiting the present invention.
3 0 p EXAMPLE 1 Solutions were prepared in accordance with the following formation: sodium dodecyl sulfate 0.105 g/L NaCI 5.0 g/L formaldehyde 55.0 g/L dextrose 112.0 g/L Phosphate Buffer 0.079 M EDTA, disodium salt 0.75 g/L water to volume S. A mixture of Na PO and Na HPO.
2 4 2 4 NaOH and/or HC1 was added to bring each portion of the S solution to the indicated pH.
Each of three solutions was prepared at a pH of 7.2 and 7.5, respectively. 250 ul of each solution was I I then rapidly mixed (within 2 seconds) with 12 ul of whole blood and incubated for 20 seconds during which time the temperature was raised to approximately 70°C. 250 ul of a Stsolution which contains 0.3% hydrogen peroxide and 125 ul of II a solution which contains 0.8% 4-chloro-l-naphthol in 20 oxydiethanol were then combined with the reaction mixtures and incubated for 20 seconds, during which time the temperature was raised to approximately 670.
The resultant solutions were than passed through an Ielectrooptical detection system and a cytogram prepared.
S Fig. 2 shows the cytogram obtained when the solution was at a pH of 6.5. This cytogram shows only the signature of red blood cells, illustrating that, at a pH of 6.5, RBCs are not lysed.
-11- Fig. 3 shows the cytogram obtained when the solution was at a pH of 7.2. This cytogram shows a very distinct white cell distribution, illustrating that, at a pH of 7.2, RBCs are lysed and white cells appropriately fixed.
Fig. 4 shows the cytogram obtained when the solution was at a pH of 7.5. This cytogram shows a significant decrease in the lymphocyte and monocyte signatures illustrating that, at a pH of 7.5, RBCs are not completely lysed.
115 StIC -12- 1 EXAMPLE II Solutions were prepared in accodance with the following formulation: sodium dodecyl sulfate 0.105 g/L NaCl 5.0 g/L Phosphate Buffer* 0.079 M formaldehyde 55.0 g/L dextrose 112.0 g/L EDTA, disodium salt 0.75 g/L water to volume S *A mixture of Na 2
HPO
4 and NaH 2
PO
4 (pH approximately The solution was divided into four portions, each of which was reacted with whole blood as described in Example I, except that the temperature to which the reaction mixture was raised was varied.
Fig. 5 shows the cytogram obtained when the temperature was 2 raised to 57 C. This cytogram shows that RBCs are not completely lysed because partially lysed RBC ghosts are masking the separation of lymphocytes from noise.
Fig. 6 shows the cytogram obtained when the temperature is raised to 60 0 C. This cytogram shows that there are still some incompletely lysed RBCs filling up the gap between lymphocytes and noise, interfering with lymphocyte discrimination from the noise..
-13- 1 Fig. 7 shows the cytogram obtained when the temperature is raised to 65 C. This cytogram shows that the RBCs are completely lysed so that the separation of lymphocytes from the noise is clear.
Fig. 8 shows the cytogram obtained when the temperature is raised to 72 C. This cytogram shows that it is at the upper limit Sof temperature. A slight inhibition of peroxidase activity of neatrophils and eosinophils is detectable.
Fig. 9 shows the cytogram obtained when the temperature is raised to 74 C. This cytogram shows that protein precipitation 15 and peroxidase denaturation have occured. The precipitate increase the noise level thereby interfering with a clear separation of lymphocytes from the noise.
Fig. 10 shows the cytogram obtained when the temperature is raised to 75 C. This cytogram shows that protein precipitation and peroxidase denaturation have occured, as exhibited by the fact that the precipitates generate noise interfering with the separation of lymphocytes and that the signatures of the neutrophils and monocytes have shifted to the left.
-14- SEXAMPLE III Solutions were prepared in accordance with the following formulation: sodium dodecyl sulfate NaCl Phosphate Buffer formaldehyde dextrose EDTA, disodium salt water 0.105 g/L 5.0 g/L 0.079 M 55.0 g/L 0.75 g/L to volume A mixture of NaH2PO4 and Na 2
HPO
4 (pH approximately Varied as described.
Four individual solutions were prepared, each having a different dextrose concentration. Each of these solutions was then reacted with whole blood as described in Example I.
Fig. 11 shows the cytogram obtained when the 0 dextrose concentration is This cytogram shows that the lymphocyte scatter signals are still too low to be clearly separated from the noise.
Fig. 12 shows the cytogram obtained when the dextrose concentration is 11.5%. This cytogram shows that the lymphocyte scatter signals are sufficiently high to be separated from the noise.
Fig. 13 shows the cytogram obtained when the dextrose concentration is 16.0%. This cytogram shows that precipitates have formed and that there is interference with 30 omplete RBC lysis.
i+ i 3″ 1 r 1 3 C1 EXAMPLE IV prepared in accordance with the Solutions were formulation: following sodium dodecyl sulfate NaC1 Phosphate Buffer formaldehyde sorbitcol EDTA, disodium salt water 0.105 g/L 5.0 g/L 0.079 M 55.0 g/L 112.0 g/L 0.75 g/L to volume A mixture of Na 2
PO
4 and Na 2
HPO
4 c NaOH and/or HC1 was added to bring each portion of the solution to the indicated pH.
The solution was divided into two portions, each of which was reacted with whole blood as described in Example I, except that the pH of each was varied.
Fig. 14 shows the cytogram obtained when the c solution was at a pH of 6.8. Fig. 15 shows the cytogram t C 20 obtained when the solution was at a pH of 7.2. Each of these S’ cytograms shows that a sugar alcohol may readily be substituted for-a sugar in the reagent solution of this invention without loss of efficacy.
28 in a sample. More particularly, the invention relates to a 29 method which comprises: S; -16- EXAMPLE V The pH stability of components of the reagent solution of this invention was tested by inclusion of components in phosphate buffer (mixture of Na 2
HPO
4 and NaH2PO4) over time at elevated temperatures. The results are shown in Table I.
c ii: A 2 -17- TABLE I In 0.1M phosphate buffer pH initial Solute Days Temp(OC) -OH f inal C C C r~ t Glucoseb Galactose b Sorbitoi b b Formaldehyde 0 Glucose b& Formaldehyde c Sorbitol b Formaldehyde c Mannitol b& Formaldehyde 0 c Control 7.5 7.5 7.5 7.4 7.2 7.2 7.2 7.4 6.2 6.0 7.5 7.5 6.7 6.7 7.1 7.1 7.4 -1.3 0 0 7 1 1 0 b Concentration C Concentration d Buffer only.
0. 7M.
1. 8M.
-18- It can readily be seen that the components, concentration and process parameters disclosed and claimed as this invention are critical to the proper determination of a differential WBC count which may be accomplished far more rapidly than prior art methods. Also, it can be seen that sugar alcohol provides more pH stability than a reducing sugar under stress conditions. The claims form part of the disclosure of the specification.

Claims (19)

1. A composition when used in determing a differential white blood cell count comprising, in admixture, an aqueous solution of: a) a surfactant; b) formaldehyde or paraformaldehyde; c) a non reducing sugar or sugar alcohol; and d) a buffer

2. The composition of claim 1 wherein the pH of the composition is from about 6.6 to about 7.6.

3. The composition of claim 1 or 2 wherein the pH of the compo- sition is from about 6.9 to about 7.3.

4. The composition of any of claims 1 to 3 wherein the buffer comprises a mixture of Na 2 HPO 4 and NaH 2 PO 4 “tt°

5. The composition of any of claims 1 to 4 wherein the surfactant is an alkali metal salt of an alkyl sulfate containing from 10 to Sz’ 16 carbon atoms.

6. The composition of claim 5 wherein the surfactant is sodium dodecyl sulfate.

7. The composition of any of claims 1 to 6 wherein the non 2 reducing sugar or sugar alcohol is sucrose, fructose, dextrose, sorbitol or mannitol.

8. The composition according to any of claims 1 to 6 wherein c) is dextrose or sorbitol.

9. The composition of any of claims 1 to 8 which contains an alkali metal chloride salt.

The composition of claim 9 wherein the alkali metal chloride salt is of NaC1, KC1 or Lid.

11. The composition of claim 10 wherein the salt is present mw.speOl3.tech 90 7 19 -L NEW-I llICP I i urr~~I L~~ 20 1 in an amount of from 68 mM to 103 mM. 2

12. The composition of any of claims 1 to 11 wherein the 3 surfactant is present in an amount from 3.1 mM to 4.5 mM, 4 the formaldehyde is present in an amount from 4.5% to 6.6% and/or the non reducing sugar or sugar alcohol is present in 6 an amount from 9.0 to 13.5%. 7

13. A process for the rapid determination of a differential 8 white blood cell count in a sample which comprises: 9 a) preparing or utilizing a reagent solution described in any of claims 1 to 12 and 18. 11 b) rapidly mixing the reagent solution with the sample to 12 be analyzed to form a reaction mixture wherein both said 13 reagent solution and said sample are initially at a 14 temperature of from 20°C to 28 0 C; and 15 c) heating the reaction mixture to a temperature of from j .i 16 62°C to 72°C within 30 seconds in order to lyse the red 17 blood cells contained in said sample. 18

14. The process of claim 13 which comprises the further 19 step of staining proxidase active white blood cells.

15. The process of claim 14 wherein the staining step 21 comprises rapidly mixing said reaction mixture with hydrogen 22 peroxide and a chromogen. 23

16. The process of claim 15 where the chromogen is 4- €c 24 chloro-l-napthol.

17. The process of any of claims 13 to 16 which further 26 comprises differentially counting the white blood cells 27 present in said sample. 28

18. A composition according to any of claims 1 to 12 for 0” 04 29 use as a reagent solution in determination of a differential 900220,!mwspe011,tech.cla, 21 white blood cell count substantially as hereinbefore described with reference to any one of the Examples.

19. A process for the rapid determination of a differential white blood cell count in a sample substantially as hereinbefore described and as defined in claim 13. DATED THIS 20th February, 1990 SMITH SHELSTON BEADLE Fellows Institute of Patent Attorneys of Australia. Patent Attorneys for the Applicant TECHNICON INSTRUMENTS CORPORATION c t f r. 900220,!mwspeOll,tech.cla,

AU62016/86A
1985-09-06
1986-08-27
Method for the determination of a differential white blood cell count

Ceased

AU602129B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US77316685A

1985-09-06
1985-09-06

US773166

1985-09-06

Publications (2)

Publication Number
Publication Date

AU6201686A

AU6201686A
(en)

1987-03-12

AU602129B2
true

AU602129B2
(en)

1990-10-04

Family
ID=25097403
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU62016/86A
Ceased

AU602129B2
(en)

1985-09-06
1986-08-27
Method for the determination of a differential white blood cell count

Country Status (7)

Country
Link

EP
(1)

EP0214613B1
(en)

JP
(1)

JPS6271857A
(en)

AU
(1)

AU602129B2
(en)

CA
(1)

CA1317533C
(en)

DE
(1)

DE3689218T2
(en)

DK
(1)

DK169529B1
(en)

ES
(1)

ES2001424A6
(en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

CA1254134A
(en)

1984-03-28
1989-05-16
Mount Sinai School Of Medicine Of The City University Of New York
Specific binding flow cytometry method

AU613642B2
(en)

1987-05-29
1991-08-08
Toa Medical Electronics Co., Ltd.
Method for classifying leukocytes and reagents

JP2635142B2
(en)

1987-05-29
1997-07-30
東亜医用電子株式会社

Leukocyte classification method and reagent

US5389549A
(en)

1987-05-29
1995-02-14
Toa Medical Electronics Co., Ltd.
Method for classifying leukocytes and a reagent used therefor

IL93565A0
(en)

1989-05-15
1990-11-29
Technicon Instr
Optical standards for automated blood analysis instruments

FR2654744B1
(en)

1989-11-20
1992-03-13
Abx Sa

REAGENT AND METHOD OF USING SAME FOR THE AUTOMATIC DETERMINATION IN FLOW CYTOMETRY OF AT LEAST ONE LEUKOCYTAIC SUB-POPULATION FROM TOTAL BLOOD.

FR2705360B1
(en)

1993-05-19
1995-08-18
Immunotech Sa

Method and composition for erythrocyte lysis, blood composition, and leukocyte analysis method.

FR2705359B1
(en)

1993-05-19
1995-08-18
Immunotech Sa

Method for protecting leukocyte cells, protective composition, protected blood composition, and blood analysis method.

JP3320869B2
(en)

1993-12-22
2002-09-03
シスメックス株式会社

Leukocyte analysis reagent

JP3324050B2
(en)

1994-10-31
2002-09-17
日本光電工業株式会社

Leukocyte classification reagent and leukocyte classification method

DE19514089C2
(en)

1995-04-13
1997-07-10
Deutsches Krebsforsch

Detection procedure for HIV-TAT

US5639630A
(en)

1995-05-16
1997-06-17
Bayer Corporation
Method and reagent composition for performing leukocyte differential counts on fresh and aged whole blood samples, based on intrinsic peroxidase activity of leukocytes

US5786224A
(en)

1995-06-29
1998-07-28
Coulter Corporation
Reagent and method for differential determination of leukocytes in blood

DE10021390C2
(en)

2000-05-03
2002-06-27
Juergen Olert

Protection solution and fixation method for the paraffin section technique

DE60133982D1
(en)

2000-06-01
2008-06-26
Matsushita Electric Ind Co Ltd

BIOSENSOR AND METHOD FOR ANALYZING BLOOD COMPONENTS

US7803523B2
(en)

2004-08-27
2010-09-28
University Health Network
Whole blood preparation for cytometric analysis of cell signaling pathways

CN102257156A
(en)

2008-12-18
2011-11-23
希森美康株式会社
Method for detecting cancer cells in blood sample

US11035763B2
(en)

2012-10-30
2021-06-15
Kanazawa Medical University
Kit for producing cleared biological specimens and method for producing cleared biological specimens

CN103674640B
(en)

2013-11-28
2017-04-05
安徽信灵检验医学科技有限公司
Formaldehyde molecule membranization buffer solution and preparation method thereof

CN111239120A
(en)

2020-02-26
2020-06-05
绍兴市人民医院
Blood calcium ion detection test paper

EP4145105A1
(en)

2021-09-06
2023-03-08
Anacyte Laboratories GmbH
Cell asservation solution

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU2813084A
(en)

1983-03-25
1984-10-09

Coulter Electronics Inc.

Method of stromatolysing reagent for the volumetric determination of populations of leukocrytes

AU4587985A
(en)

1984-09-24
1986-04-10

Technicon Instruments Corportion

Leukocyte differentiation composition and method

AU5361886A
(en)

1980-06-16
1986-07-24

Coulter Electronics Inc.

Multipurpose blood dilutent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US409917A
(en)

1889-08-27

Plumb-bob

US3741875A
(en)

1970-10-30
1973-06-26
Mount Sinai Res Foundation Inc
Process and apparatus for obtaining a differential white blood cell count

US4040785A
(en)

1976-10-18
1977-08-09
Technicon Instruments Corporation
Lysable blood preservative composition

DE3225408A1
(en)

1982-07-07
1984-01-12
Biotest-Serum-Institut Gmbh, 6000 Frankfurt

AQUEOUS SOLUTION FOR SUSPENDING AND STORING CELLS, ESPECIALLY ERYTHROCYTES

1986

1986-08-27
AU
AU62016/86A
patent/AU602129B2/en
not_active
Ceased

1986-09-02
DK
DK419286A
patent/DK169529B1/en
not_active
IP Right Cessation

1986-09-03
CA
CA000517378A
patent/CA1317533C/en
not_active
Expired – Fee Related

1986-09-03
DE
DE19863689218
patent/DE3689218T2/en
not_active
Expired – Fee Related

1986-09-03
EP
EP19860112197
patent/EP0214613B1/en
not_active
Expired – Lifetime

1986-09-04
ES
ES8601896A
patent/ES2001424A6/en
not_active
Expired

1986-09-06
JP
JP21052686A
patent/JPS6271857A/en
active
Granted

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU5361886A
(en)

1980-06-16
1986-07-24
Coulter Electronics Inc.
Multipurpose blood dilutent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes

AU2813084A
(en)

1983-03-25
1984-10-09
Coulter Electronics Inc.
Method of stromatolysing reagent for the volumetric determination of populations of leukocrytes

AU4587985A
(en)

1984-09-24
1986-04-10
Technicon Instruments Corportion
Leukocyte differentiation composition and method

Also Published As

Publication number
Publication date

JPH0511855B2
(en)

1993-02-16

EP0214613B1
(en)

1993-10-27

DE3689218T2
(en)

1994-05-19

ES2001424A6
(en)

1988-05-16

EP0214613A3
(en)

1989-07-26

DK169529B1
(en)

1994-11-21

AU6201686A
(en)

1987-03-12

EP0214613A2
(en)

1987-03-18

DK419286A
(en)

1987-03-07

DK419286D0
(en)

1986-09-02

JPS6271857A
(en)

1987-04-02

CA1317533C
(en)

1993-05-11

DE3689218D1
(en)

1993-12-02

Contact information